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ORIGINAL ARTICLE
Factor 11 single-nucleotide variants in women with heavy menstrual bleeding
Sophie Wiewel-Verschuerena,b, Andre B. Mulderc, Karina Meijera and Rene Mulderc
aDivision of Thrombosis and Haemostasis, Department of Hematology, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands; bDepartment of Obstetrics and Gynaecology, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands; cDepartment of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen,
The Netherlands
ABSTRACT
In a previous study it was shown that lower factor XI (FXI) levels in women with heavy menstrual bleed-
ing (HMB). Our aim was to determine the single-nucleotide variants (SNVs) in the F11 gene in women
with HMB. In addition, an extensive literature search was performed to determine the clinical signifi-
cance of each SNV. Patients referred for HMB (PBAC-score >100) were included. With direct sequencing
analysis of all 15 exons and flanking introns of the F11 gene, 29 different non-structural SNVs were
detected in 49 patients with HMB. Interestingly, most of these SNVs have previously been associated
with venous thrombosis instead of bleeding. These findings have not helped to elucidate the molecular
basis of HMB. They also question the specificity of previously reported F11 variations in patients with
thrombosis. More studies are needed to explain the lower FXI levels seen in patients with HMB.
IMPACT STATEMENT
 Women with mild deficiencies of factor XI (FXI) (< 70%) are prone to excessive bleeding during
menstruation. Bleeding manifestations are not well correlated with plasma FXI levels and bleeding
episodes can vary widely among patients with similar low FXI levels. In a previous study we showed
that women with heavy menstrual bleeding (HMB) had normal, but on average, lower levels of FXI
than controls.
 In light of these findings, we performed F11 gene analysis to determine the single-nucleotide var-
iants (SNVs) in women with HMB and performed an extensive literature search to determine the
clinical significance of each SNV. By direct sequencing analysis of the F11 gene we found 29 differ-
ent non-structural SNVs in 49 women with heavy menstrual bleeding. Remarkably, a number of
these SNVs have previously been implicated in thrombosis.
 These findings have not helped to elucidate the molecular basis of lower FXI levels in HMB. They
also question the specificity of previously reported F11 variations in patients with thrombosis. More






Factor XI (FXI 2014) deficiency, also known as haemophilia C,
is an autosomal bleeding disorder characterised by reduced
plasma levels of FXI with a high prevalence (about 9%) in the
Ashkenazi Jewish population (Bolton-Maggs 2009). The preva-
lence of FXI deficiency in Caucasians is reported as low, but
might be underestimated (Mitchell et al. 2006; Zadra et al.
2008). Women with low levels of FXI (<70%) are prone to
excessive bleeding during menstruation. However, bleeding
manifestations are not well correlated with plasma FXI levels
and bleeding episodes can vary widely among patients with
similar low FXI levels (O’Connell 2003; Bolton-Maggs 2009).
To date, more than 200 mutations have been reported
(http://www.factorxi.org).
In plasma, FXI circulates as a homodimeric precursor of a
serine protease (FXIa), which plays an essential role in the
contact activation of coagulation through the conversion of
FIX to FIXa in a calcium-dependent manner (Davie et al.
1991). Each FXI monomeric structure contains a heavy chain
and a light chain that are joined together by disulphide
bonds. The heavy chain contains four apple domains and the
light chain contains the serine protease domain (Fujikawa
et al. 1986). The fourth apple domain is necessary for dimer-
isation (Meijers et al. 1992).
The F11 gene is located on the long arm of chromosome
4 (4q35) and contains 15 exons and 14 introns (Asakai et al.
1987). Exon 1 encodes the untranslated region (UTR), whereas
the exon 2 encodes the signal peptide. All four apple
domains are encoded in exons 3 to 10. Exons 11 to 15
encode the serine protease domain.
In our previous study (Knol et al. 2013), a 4% FXI defi-
ciency (<70%) was found in unselected Dutch women with
heavy menstrual bleeding (HMB). It was also found that
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patients had significantly longer activated partial thrombo-
plastin time compared to controls (26.5 vs 25.0 s; p¼ .001),
despite higher levels of factor VIII. This turned out to be
caused by lower median levels of FXI (100 vs 124%; p< .001).
In light of these findings, F11 gene analysis was performed
to determine the single-nucleotide variants (SNVs) in women
with HMB. In addition, an extensive literature search was per-




Patients referred for heavy, regular menstrual periods were
included. Exclusion criteria were Pictorial Blood loss
Assessment Chart-score <100 (Higham et al. 1990; Janssen
et al. 1998), known bleeding disorder, use of any intrauterine
device within 2months prior to inclusion and treatment with
antifibrinolytics, anticoagulants, non-steroidal anti-inflamma-
tory agents, progestagens or combined oral contraceptives.
Eligible women were asked to fill out a structured question-
naire for medical, obstetrical and gynaecological history,
including all items of the Tosetto bleeding score (Rodeghiero
et al. 2007). Eligible women were invited to our clinic and
had a gynaecological examination and pelvic ultrasonography
in the first week after the menstruation. The study was
approved by the Institutional Review Board of the University
Medical Center of Groningen. Informed consent was obtained
from all patients.
Blood collection and sample preparation
Venous blood was taken from all patients in the first week
after the menstruation. The blood samples were taken before
the gynaecological examination. Blood samples were anticoa-
gulated with a 1:10 volume of 0.109M trisodium citrate.
Platelet-poor plasma was prepared by centrifugation at
2500g for 15min, aliquoted and immediately frozen at
80 C, and analysed after rapid thawing at 37 C. Genomic
DNA was obtained from peripheral blood samples using the
Qiacube system.
FXI assay
FXI activity levels were determined by a one-stage clotting
assay (Siemens, Marburg, Germany). Reference interval was
65–150%.
PCR amplification and sequencing
PCRs were performed for each of the 15 exons and flanking
introns. Primers are indicated in Table 1. Reactions (25 ll) for
all PCRs except for exon 9 and 14 contained 1 ll of primer
(20 pmol), 1.6 ll of MgCl2 (25mM), 0.3 ll of dNTPs (25mM),
0.4ll of Faststart Taq (5Ul/ll), 5ll of 5GC-rich solution,
2.5ll of 10 PCR-buffer (–MgCl2), 11.2 ll of DEPC H20 and
2ll of DNA (10 ng). For exons 9 and 14, 1ll instead of 1.6ll
of MgCl2 (25mM) was used. The PCR protocol for exons 9
and 14 started with denaturation for 5min at 94 C, followed
by 40 cycles at 94 C for 30 s, 55 C for 30 s and 70 C for
1min. The cycling protocol of the remaining exons was
almost the same, only the annealing temperature was 49 C
instead of 55 C, and the amount of cycles was 35 instead of
40. M13-tailed primers enabled the use of standardised ampli-
fication conditions for the sequencing PCR (96 C for 1min,
30 cycles at 96 C for 30 s, 55 C for 15 s and 60 C for 2min).
The sequencing PCR was performed on both strands using
Big Dye terminators V1.1 and an ABI 3130xl analyser. The
chromatograms were analysed with CLC main workbench.
Nomenclature
The nomenclature was according to the guidelines of the
Human Genome Variation Society. For cDNA numbering,
nucleotide 1 is the A of the ATG translation initiation codon
(c.1). For amino acid numbering, the ATG initiation codon
corresponds to the first amino acid (p.1).
Literature search
To determine the clinical significance of each SNV, a search
in PubMed was performed to identify all relevant references
for each SNV. More specifically, references were included if a
significant clinical association was reported, if molecular gen-
etic analysis was performed to identify causal F11 gene
defects, if structural features of a specific variant were ana-
lysed, or when haplotype analysis was performed with spe-
cific variants. Based on these criteria, references were
categorised in association studies and molecular analysis.
Table 1. Primers.
Primer sequence (50 > 30) Position
Exon 1F CCAAAGTCTCCTCCCTCCAT 130 to 110
Exon 1R TGTTGTTCCACATTTCCTCTCA 169 to 191
Exon 2F AGAAGGATCTGAACACAGAGAGC 299 to 276
Exon 2R CCTGCTTTGAAAACCTCTGG 189 to 209
Exon 3F GTTTCCACCTGAGGCTGTTC 181 to 161
Exon 3R TTGCGTAAACACCATCACTTC 145 to 166
Exon 4F CAGTCAGGCTAAACAGAAACACACAGA 286 to 263
Exon 4R GGGGGTTTATTTCCACATAGC 92 to 113
Exon 5F CTGAGGAAAGGTGGGTGAAA 110 to 90
Exon 5R GCGCTTTTGAAATTAGCCAAG 231 to 252
Exon 6F TGAGAAGGGCTTGAGAAGTCA 272 to 251
Exon 6R TCCGTTTCATCGTGAGCATA 81 to 101
Exon 7F ACCAGCTTATGCTCACGATG 260 to 240
Exon 7R GAAAGGGAGAGGGGCTAGAA 128 to 148
Exon 8-9F ACCTAAGGGCCATGGAGTGT 191 to 171
Exon 8-9R CATTGGTGCACAGTTTCTGG 84 to 104
Exon 9-10F TGCTGTCTAGTGTTCTGCCATT 10 to 11
Exon 9-10R TGGTCAGCTTGAGTGACAGG 142 to 162
Exon 11F ATGTTTTGCTTTGGCAGCTT 158 to 138
Exon 11R GCCTTGTACCTGCACCTGTT 176 to 196
Exon 12F TGTCCATCATTGGCAGAAAA 113 to 93
Exon 12R AGCCAGGAAAGTGTGTCAGC 154 to 174
Exon 13F GCAACTTGTGCAGGATCAAA 256 to 236
Exon 13R TTGGGTGATTTTTGCCTCTC 133 to 153
Exon 14F ATGGTTATTCTACAAACGAACCAAA 39 to 14
Exon 14R TCCTTGCTTTTGATTTCAGTCTAAG 451 to 476
Exon 15F AAGACAACATTTTAGGCAAAATCAG 100 to 75
Exon 15R TTTCTTCCAGTTTTCATCTTTCATC 207 to 232
M13F TGTAAAACGACGGCCAGT na
M13R CAGGAAACAGCTATGACC na
Exon 9–10 F is partly bound within exon 9.




























A reference search was performed starting with the SNV
reference id (rs-code). To identify rs-codes, a selection of the
F11 gene sequence containing the base pair change was
paste in mutationtaster (http://mutationtaster.org/) and a
search was performed using NCBI gene ID 2160 and Ensembl
transcript ID ENST0000403665. If no references were recov-
ered for the rs-codes, additional keywords such as base pair
change (c.), amino acid change (p.), gene name, FXI defi-
ciency, polymorphism, association studies or GWAS were
used. In addition, each reference including supplementary
data was screened for additional SNVs. Finally, it is worth not-
ing that despite using the above mentioned keywords no
references may be retrieved. This may be caused by the fol-
lowing: (1) in several publications the coding sequence num-
bering is according to Fujikawa, i.e. 43 bp (Fujikawa et al.
1986); (2) some SNVs such as rs4253398 and rs3822057 have
been given a different base change position, i.e. 231 T>C,
and 138 C>A, respectively; (3) most amino acid changes
are indicated after the signal peptide is cleaved (18).
Results
49 patients were included with a median age of 44 years
(range: 26–54). Median FXI level was 96% (range 61%–155%);
vs 124% in our previously published menstrual cycle-matched
controls (Knol et al. 2013). In 53% of the patients, the FXI
level was <100% (Table 2). In 2 patients FXI levels below the
normal range of 65% were found. One patient (number 46 in
the supplementary table S1) had a level of 61% factor XI,
which was in the normal range (83%) when the measurement
was repeated and one patient had a FXI of 64%, which was
not repeated. None of these 49 patients had a history of
deep venous thrombosis. In total, 29 different non-structural
SNVs were identified in 49 patients (Table 3).
Non-synonymous variants
Two non-synonymous variants were identified: rs5969
(p.Gln244Arg) and rs202061241 (p.Val615Met). Rs5969 is the
result of an A to G substitution at nucleotide 731 in exon 7.
This mutation was first described by Martincic et al.
(Martincic et al. 1998; Erratum 1999). This paper reports on
the genetic analysis of F11 gene in two African–American
patients with mild FXI deficiency and one patient of
European Jewish ancestry with severe FXI deficiency (patient
3). This last patient was included in the study as an abnormal
control. The propositus, a 9-year-old boy with a history of
excessive bleeding and mild FXI deficiency, was compound
heterozygous for rs5969 and rs145168351 (p.Ser266Asn). His
mother was heterozygous for rs145168351, and also experi-
enced excessive bleeding. Besides being compound
heterozygous for type II (rs121965063, p.Glu135Ter) and type
III (rs121965064, p.Phe301Leu) variants, the abnormal control
did not contain the other two non-synonymous variants. The
binding affinity between FXI and FIX (Km) differed consider-
ably from wild-type FXI (Sun et al. 2001). However, rs5969
was associated with FXI activity levels comparable to wild-
type when tested in an APTT-based assay (Martincic et al.
1998). In line with this, the catalytic efficiency (kcat) for FIX
activation was shown to be comparable to that of wild-type
FXI, thus normalising the APTT result (Sun et al. 2001).
Various clinical studies as well as studies that examined the
structural features of rs5969 have confirmed the minimal
effect (Mitchell et al. 1999; Mitchell et al. 2003; O'Connell
et al. 2005; Mitchell et al. 2006; Saunders et al. 2009).
Therefore, our findings were in accordance with the normal
FXI level (83%) was found in our patient. Rs202061241 is
caused by a G to A substitution at nucleotide 1843 in exon
15, which is located in the protease domain. To our know-
ledge, no clinical data on this mutation has been reported.
Therefore, PROVEAN (2014) (http://provean.jcvi.org/index.php)
was used to determine the functional effects of this mutation.
With a score of 0.276, this mutation was said to be neutral
(default threshold 2.5). This finding supports the FXI level
(93%) found in this patient.
Synonymous variants
Our study detected six synonymous variants. One patient (FXI
level: 96%) was heterozygous for a SNV in exon 5
(c.423G>A), maintaining the threonine at amino acid pos-
ition 141 in the second apple domain (p.Thr141¼). This vari-
ant had no reference ID, though it was found in the Exome
Aggregation Consortium (Exac) Browser (http://exac.broadin-
stitute.org/), with an allele frequency of 0.000008243.
A missense mutation at this position, resulting in a threo-
nine to methionine substitution has been described in com-
bination with the nonsense mutation p.Glu135Ter in a severe
FXI-deficient patient from the Abruzzo region in Italy
(Castaman et al. 2008).
The five other synonymous variants (rs5973, rs5974,
rs5970, rs5971 and rs5976) have been extensively used as
markers for haplotype analysis (Bolton-Maggs et al. 2004;
Quelin et al. 2004; Zadra et al. 2004; Zadra et al. 2008; Kim
et al. 2012; Bicocchi et al. 2013), which is not surprising as
three (rs5973, rs5974 and rs5970) are in marked linkage dis-
equilibrium with one another (Tarumi et al. 2000). These
three neutral variants were initially reported by Martincic
et al. (1998).
Non-coding variants
Twenty-one SNVs were located in the non-coding regions of
the F11 gene. Based on the literature search (Table 3), these
variants have mostly been mentioned in the context of the
risk of venous thrombosis. Among these variants, rs2289252
was most frequently reported to be independently associated
with venous thrombosis. Furthermore, rs2289252 was associ-
ated with miscarriages, decreased APTT and high FXI levels.
Table 2. Patient characteristics.
Patients (n¼ 49)
Age in years, median (range) 44 (26 to 54)
PBAC-score in points, median (Q1–Q3) 272 (204 to 557)
FXI level in %, median (Q1–Q3) 96 (88 to 118)
FXI level <100%, n (%) 26 (53)
Tosetto bleeding score in points, median (range) 0 (2 to 7)
PBAC: Pictorial Blood loss Assessment Chart; FXI: Factor XI.




























Table 3. Single-nucleotide variants.
Association studies Molecular analysis
dbsnp Base change AA change Region Trait Association Reference Causal Reference
rs771153790 c.423G>A p. Thr141¼ Exon 5 NR NR NR NR NR
rs5973 c.429C> T p.Asp143¼ Exon 5 VTE N (Gerdes et al. 2004) N (Martincic et al. 1998)a,
(Ventura et al. 2000;
Zivelin et al. 2002;
Bezak et al. 2005; Zadra
et al. 2008; Bicocchi
et al. 2013)
rs5969 c.731A>G p.Gln244Arg Exon 7 NR NR NR N (Martincic et al. 1998)a,
(Mitchell et al. 1999;
Sun et al. 2001; Mitchell
et al. 2003; O'Connell
et al. 2005; Mitchell
et al. 2006; Saunders
et al. 2009)
rs5974 c.801A>G p.Thr267¼ Exon 8 VTE N (Gerdes et al. 2004;
Bezemer et al. 2008)
N (Martincic et al.
1998)a,(Ventura et al.
2000; Zivelin et al. 2002;
Zadra et al. 2004; Zadra
et al. 2008; Kim et al.
2012; Bicocchi et al.
2013)
rs5970 c.1191T> C p.Gly397¼ Exon 11 VTE N (Gerdes et al. 2004) N (Zivelin et al. 2002; de
Moerloose et al. 2004;
Zadra et al. 2004; Bezak
et al. 2005; Jayandharan
et al. 2005; Zadra et al.
2008; Kim et al. 2012;
Bicocchi et al. 2013),
(Martincic et al. 1998)a
rs5971 c.1812G> T p.Arg604¼ Exon 15 VTE N (Gerdes et al. 2004;
Bezemer et al. 2008;
Germain et al. 2011;
Morange et al. 2011)
N (Quelin et al. 2004; Zadra
et al. 2004, 2008; Fard-
esfahani et al. 2008;
Kim et al. 2012; Bicocchi
et al. 2013)
rs5976 c.1839G>A p.Glu613¼ Exon 15 VTE N (Gerdes et al. 2004) N (Zivelin et al. 2002; Quelin
et al. 2004; Zadra et al.
2004; Zadra et al. 2008;
Bicocchi et al. 2013)
rs202061241 c.1843G>A p.Val615Met Exon 15 NR NR NR NR NR
rs3733403 c.-316C>G UTR 5 VTE/Stroke N and?/Y (Bezemer et al. 2008;
Reiner et al. 2009;
Hanson et al. 2013)
? (Tarumi et al. 2003; Quelin
et al. 2006)
rs3822056 c.-446G> T nearGene-5 VTE/APTT N and?/N (Bezemer et al. 2008;
Morange et al. 2011)
? (Tarumi et al. 2002, 2003;
Quelin et al. 2006)
rs925451 c.-2þ 120G>A Intron 1 VTE/HDP/
APTT/Stroke
Y and N/?/Y/Y (Sato et al. 2006; Li et al.
2009; Delluc et al. 2010;
Germain et al. 2011;
Morange et al. 2011;
Hanson et al. 2013)
N (Quelin et al. 2004)
rs4253398 c.-1-229T> C Intron 1 NR NR NR N (Ventura et al. 2000;
Zivelin et al. 2002;
Bolton-Maggs et al.
2004; Zadra et al. 2004;
Zadra et al. 2008; Kim
et al. 2012)
rs4253399 c.-1-196T>G Intron 1 VTE/APTT/FXI Y and N/?/? (Li et al. 2009; Sabater-
Lleal et al. 2012; Tang
et al. 2013)
N (Kim et al. 2012)
rs3841991 c.-1-148_-1-
147insAT
Intron 1 NR NR NR NR NR
rs3822057 c.-1-138A> C Intron 1 VTE Y, N, and? (Smith et al. 2007; Li et al.
2009; Arellano et al.
2010; de Haan et al.
2012; van Hylckama
Vlieg et al. 2014)
N (Zivelin et al., 2002;
Bolton-Maggs et al.
2004; Zadra et al. 2004,
2008; Jayandharan
et al., 2005; Kim et al.
2012), (Ventura et al.
2000)a
rs1593 c.485þ 122T> A Intron 5 VTE/APTT/Stroke N and?/Y/Y (Bezemer et al. 2008; Li
et al. 2009; Dahm et al.
2012; Tang et al. 2012;
Hanson et al. 2013)
NR NR
rs4253410 c.485þ 181T> C Intron 5 NR NR NR NR NR
rs4253414 c.486-88T> C Intron 5 VTE N (Bezemer et al. 2008) NR NR
(continued)




























This SNV is located in intron 12 (c.1481–188) and the result
of a C> T substitution. Eight other SNVs, including rs1593,
rs3822057, rs925451, rs4253430, rs4253414, rs4253399,
rs3733403 and rs3822056 also showed an association with
venous thrombosis. Interestingly, all these SNVs are in linkage
disequilibrium with rs2289252 (SNAP, 1000 genomes,
Bioinformatics).
It is tempting to speculate that an overexpression of these
variants could compensate for low FXI level in these patients
and may reset the haemostatic balance to a less-haemophilic
phenotype. To test this hypothesis, the allele frequencies of
all SNVs between high (> 100%) and low (<100%) FXI levels
were compared using the Fisher Exact probability test in a
2 3 contingence table. A p value of less than .05 indicated
significance. No significant difference was observed between
both the groups. Moreover, even when the lowest percentile
was taken and compared to the rest this difference remained
non-significant.
Two identified SNVs in high LD (rs373403 and rs3822056)
are located in the promotor region of the F11 gene. In our
cohort, nine patients had one or both of these SNVs with a
median FXI level of 96% (range 61%–129%). Rs373403, a vari-
ant that is caused by a C to G base change at c.-316, has
been shown to negatively affect the transcription binding
(Tarumi et al. 2003). However, the overall effect is probably
low, because a region between 381 and 363 bp upstream of
exon 1, is responsible for maximum promotor activity in
HepG2 hepatocellular carcinoma cells (Tarumi et al. 2002).
This region contains the sequence ACTTTG that has been
identified in several gene promotors of coagulation factors
for being the binding site for transcription factor hepatocyte
nuclear factor 4 (HNF4) (Reijnen et al. 1992; Erdmann and
Heim 1995; Hung and High 1996). Also, no variant was
located at the binding site for miR-181a-5p, a microRNA
which is inversely correlated with F11 mRNA levels (Salloum-
Asfar et al. 2014).
Discussion
This study was performed because it was shown (Knol et al.
2013) that women with HMB had lower mean FXI levels than
menstrual cycle-matched controls. 29 different non-structural
SNVs were detected in 49 patients with HMB.
Additionally, the SNVs found in our patient group were
also compared with the literature. Literature shows that F11
gene analysis is mainly carried out in the context of the risk
of deep venous thrombosis and elevated levels of FXI. Most
SNVs that were found are therefore already described in rela-
tionship with either venous thrombo-embolism, stroke,
decreased APTT, hypertensive disorders in pregnancy, higher
FXI levels or miscarriages. Remarkably, our results show that
these SNVs are also present in women with HMB and thus in
a group with increased bleeding tendency. Noteworthy is
that none of the women in our study had a previous VTE.
This result directly undermines the assumed relationship
between these SNVs and venous thrombosis.
A limitation of our study is that the patient group is small.
As a consequence it was impossible to provide haplotype
data and multiple comparisons could not be made.
Nonetheless, this is the first study which gives an overview of
the molecular background of the F11 gene, as found in
patients with HMB. Therefore, our group can serve as a refer-
ence group for future studies. Another limitation is that it
Table 3. Continued
Association studies Molecular analysis
dbsnp Base change AA change Region Trait Association Reference Causal Reference
rs4253840 c.486-181C> T Intron 5 NR NR NR NR NR
rs116667976 c.1304þ 12G>A Intron 11 NR NR NR NR NR
rs2289251 c.1481-215C> T Intron 12 NR NR NR NR NR
rs2289252 c.1481-188C> T Intron 12 (Recurrent) VTE/
APTT/FXI/
Miscarriage
Y, N and?/Y/Y/N (Smith et al. 2007; Reiner
et al. 2009; Li et al.
2009; Smith et al. 2009;
Delluc et al. 2010;
Arellano et al. 2010;
Dahm et al. 2012; de
Haan et al. 2012;
Lunghi et al. 2012; Tang
et al. 2012; El-Galaly
et al. 2013; van
Hylckama Vlieg et al.
2014; Rovite et al. 2014;
Sokol et al. 2014;
Bruzelius et al. 2015a,b)
NR NR
rs2289253 c.1481-34G> T Intron 12 NR NR NR N (Kim et al. 2012)
rs2289254 c.1576þ 51C>A Intron 12 NR NR NR NR NR
rs4253427 c.1716þ 248G> A Intron 14 NR NR NR NR NR
rs4253428 c.1716þ 250G> A Intron 14 NR NR NR NR NR
rs74536324 c.1716þ 252C> T Intron 14 NR NR NR NR NR
rs4253429 c.265A>G UTR 3 NR NR NR NR NR
rs4253430 c.296G> C UTR 3 VTE N and? (Bezemer et al. 2008; Li
et al. 2009)
NR NR
NR: not reported; associations are indicated by Y: significant, N: non-significant or?: doubtful; VTE: venous thromboembolus; APTT: activated partial thromboplastin
time; HDP: hypertensive disorders in pregnancy; FXI: factor XI.
aThe first report on this single-nucleotide variant.




























was not possible to compare the patients with a control
group of women with a normal amount of blood loss during
their menstruation. However, it was possible to compare the
FXI levels of our patients with a control group from our previ-
ous study (Knol et al. 2013). In addition, because most of the
SNVs that were found have previously been described, an
extensive literature search was performed to determine the
clinical significance of each SNV.
Conclusions
By direct sequencing analysis of the F11 gene, 29 different
non-structural SNVs were found in 49 women with HMB.
These findings have not helped to elucidate the molecular
basis of HMB. They also question the specificity of previously
reported F11 variations in patients with thrombosis. More
studies are needed to explain the lower FXI levels seen in
patients with HMB.
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